The 8 analysts offering 12-month price forecasts for Myriad Genetics Inc have a median target of 19.50, with a high estimate of 25.00 and a low estimate of 13.00. The median estimate represents a +1.83% increase from the last price of 19.15.
The current consensus among 9 polled investment analysts is to Hold stock in Myriad Genetics Inc. This rating has held steady since November, when it was unchanged from a Hold rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.15
Reporting Date Feb 23
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.